A Phase II Study of Oral Idarubicin (4-Demethoxidaunorubicin) in Previously Untreated Elderly Patients with Non-Hodgkinʼs Lymphoma
- 1 June 1991
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 14 (3) , 243-245
- https://doi.org/10.1097/00000421-199106000-00011
Abstract
Eighteen untreated elderly patients (median age 75 years) with non-Hodgkin's lymphoma (NHL) entered a phase II study with oral Idarubicin (4-demethoxidaunorubicin) at a dosage of 30-35 mg/m2 on day 1 and every 3 weeks thereafter. The medium number of cycles administered was three (range one to nine). We obtained one (6%) complete response and four (25%) partial responses in 16 evaluable patients. Toxicity was mild and no cardiotoxicity was found. At this dosage Idarubicin showed little anticancer activity in NHL.Keywords
This publication has 0 references indexed in Scilit: